OCUL Key Statistics, Chart & Performance
The current stock price of OCUL is 9.16 USD. In the past month the price decreased by -12.18%. In the past year, price increased by 25.82%.
OCUL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OCUL. When comparing the yearly performance of all stocks, OCUL turns out to be only a medium performer in the overall market: it outperformed 49.46% of all stocks.
OCUL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OCUL. OCUL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
OCUL Financial Highlights
Over the last trailing twelve months OCUL reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 5.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.77% | ||
| ROE | -96.69% | ||
| Debt/Equity | 0.27 |
OCUL Forecast & Estimates
19 analysts have analysed OCUL and the average price target is 24.82 USD. This implies a price increase of 170.96% is expected in the next year compared to the current price of 9.16.
For the next year, analysts expect an EPS growth of -1.87% and a revenue growth -14.17% for OCUL
OCUL Ownership
OCUL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.25 | 969.015B | ||
| JNJ | JOHNSON & JOHNSON | 20.67 | 574.257B | ||
| MRK | MERCK & CO. INC. | 22.05 | 290.769B | ||
| PFE | PFIZER INC | 9.23 | 156.982B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.85 | 123.896B | ||
| ZTS | ZOETIS INC | 18.74 | 56.466B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.53 | 25.52B | ||
| VTRS | VIATRIS INC | 6.38 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.59 | 12.725B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.37 | 9.291B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OCUL
Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Company Info
OCULAR THERAPEUTIX INC
15 Crosby Drive
Bedford MASSACHUSETTS 01730 US
CEO: Antony Mattessich
Employees: 274
Phone: 17813574000
OCULAR THERAPEUTIX INC / OCUL FAQ
What does OCULAR THERAPEUTIX INC do?
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Can you provide the latest stock price for OCULAR THERAPEUTIX INC?
The current stock price of OCUL is 9.16 USD. The price increased by 1.44% in the last trading session.
Does OCULAR THERAPEUTIX INC pay dividends?
OCUL does not pay a dividend.
What is the ChartMill technical and fundamental rating of OCUL stock?
OCUL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the ownership structure of OCULAR THERAPEUTIX INC (OCUL)?
You can find the ownership structure of OCULAR THERAPEUTIX INC (OCUL) on the Ownership tab.
Can you provide the short interest for OCUL stock?
The outstanding short interest for OCULAR THERAPEUTIX INC (OCUL) is 6.18% of its float.